MX2015013275A - Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevencion de enfermedades o afecciones asociadas con difucion mitocondrial. - Google Patents

Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevencion de enfermedades o afecciones asociadas con difucion mitocondrial.

Info

Publication number
MX2015013275A
MX2015013275A MX2015013275A MX2015013275A MX2015013275A MX 2015013275 A MX2015013275 A MX 2015013275A MX 2015013275 A MX2015013275 A MX 2015013275A MX 2015013275 A MX2015013275 A MX 2015013275A MX 2015013275 A MX2015013275 A MX 2015013275A
Authority
MX
Mexico
Prior art keywords
selenium
same
compositions
disease
prevention
Prior art date
Application number
MX2015013275A
Other languages
English (en)
Other versions
MX359626B (es
Inventor
Stefan Kwiatkowski
Ronan Power
Casey Egan
Alexander Yiannikouris
Zi-Jian Lan
Rijin Xiao
Lewis Collen Jackson
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of MX2015013275A publication Critical patent/MX2015013275A/es
Publication of MX359626B publication Critical patent/MX359626B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

La presente solicitud se relaciona con composiciones que comprenden selenio (por ejemplo, levadura enriquecida con selenio y compuestos que contienen selenio obtenidos o derivados de esta) y métodos para utilizar las mismas para tratar e inhibir obesidad, diabetes y afecciones relacionadas. En particular, la presente solicitud proporciona composiciones que comprenden levadura enriquecida con selenio (por ejemplo, levadura enriquecida con selenio que comprende 2% o menos de selenio orgánico), compuestos que contienen selenio presente allí y/o derivados de este, y métodos para utilizar las mismas para mejorar la actividad y función mitocondrial (por ejemplo, en el sistema músculo esquelético e hígado) en un sujeto (por ejemplo, como un tratamiento terapéutico y/o profiláctico para diabetes, obesidad y afecciones relacionadas).
MX2015013275A 2013-03-15 2014-03-14 Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial. MX359626B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
MX2015013275A true MX2015013275A (es) 2015-12-11
MX359626B MX359626B (es) 2018-10-01

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013275A MX359626B (es) 2013-03-15 2014-03-14 Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial.

Country Status (15)

Country Link
US (1) US9833486B2 (es)
EP (1) EP2968404A4 (es)
JP (1) JP6313418B2 (es)
KR (1) KR102245702B1 (es)
CN (3) CN114533753A (es)
AU (1) AU2014228785B2 (es)
BR (1) BR112015022514A2 (es)
CA (1) CA2903845C (es)
CL (1) CL2015002677A1 (es)
HK (1) HK1216506A1 (es)
MX (1) MX359626B (es)
RU (1) RU2663127C2 (es)
SG (2) SG10202101918RA (es)
WO (1) WO2014144776A1 (es)
ZA (1) ZA201506759B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152795A2 (en) 2013-03-14 2014-09-25 Schentag Jerome J Cholestosome vesicles for incorporation of molecules into chylomicrons
KR102466389B1 (ko) * 2014-03-14 2022-11-11 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3429373A4 (en) * 2016-03-14 2019-07-17 Mitogenetics, LLC MATERIALS AND METHOD FOR TREATING HYPOXIC CONDITIONS
BR112019022918A2 (pt) 2017-05-19 2020-05-26 Alltech, Inc. Agentes farmacêuticos, composições e métodos relativos aos mesmos
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302A (zh) * 2023-03-31 2023-06-27 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
WO2004107881A1 (en) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008144543A2 (en) * 2007-05-18 2008-11-27 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
NZ583025A (en) * 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
ES2378595T3 (es) * 2007-10-16 2012-04-16 Actigenomics S.A. Composición destinada a la regulación del metabolismo de los lípidos
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
WO2011047434A1 (en) * 2009-10-22 2011-04-28 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
US8883498B2 (en) * 2010-04-22 2014-11-11 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
KR102100091B1 (ko) 2011-04-13 2020-04-14 아지노모토 가부시키가이샤 영양 조성물

Also Published As

Publication number Publication date
US9833486B2 (en) 2017-12-05
ZA201506759B (en) 2017-03-29
NZ711842A (en) 2021-04-30
SG10202101918RA (en) 2021-03-30
CA2903845A1 (en) 2014-09-18
CN105377271A (zh) 2016-03-02
CA2903845C (en) 2022-08-23
CN114984038A (zh) 2022-09-02
HK1216506A1 (zh) 2016-11-18
EP2968404A1 (en) 2016-01-20
RU2663127C2 (ru) 2018-08-01
EP2968404A4 (en) 2017-01-04
JP2016516058A (ja) 2016-06-02
KR20150132374A (ko) 2015-11-25
CL2015002677A1 (es) 2016-12-09
KR102245702B1 (ko) 2021-04-28
BR112015022514A2 (pt) 2017-07-18
RU2015139742A (ru) 2017-04-21
SG11201507061XA (en) 2015-10-29
CN114533753A (zh) 2022-05-27
MX359626B (es) 2018-10-01
US20160113977A1 (en) 2016-04-28
JP6313418B2 (ja) 2018-04-18
WO2014144776A1 (en) 2014-09-18
AU2014228785A1 (en) 2015-09-24
AU2014228785B2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX359626B (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial.
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MY197024A (en) Amylin analogues
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX2017011182A (es) Analogos de amilina.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX366368B (es) Metodos para el cuidado oral prebiotico usando un sacarido.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
WO2012135528A3 (en) Galectin-3c combination therapy for human cancer
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.

Legal Events

Date Code Title Description
FG Grant or registration